The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
DPO Minutes to Be Disclosed 2 Months after Chuikyo General Assembly
The Central Social Insurance Medical Council (Chuikyo) on September 15 approved disclosure rules for the minutes of drug pricing and cost-effectiveness assessment organizations in a move responding to criticism at the government’s administrative project review last year. During the administrative…
To read the full story
Related Article
- MHLW Publishes Members’ Names of DPO; Disclosure of Minutes Expected as Early as Summer
January 25, 2021
- MHLW to Disclose Members’ Names, Minutes of Drug Pricing, Cost-Effectiveness Analysis Organizations to Enhance Transparency
December 24, 2020
- Experts Urge Transparency for DPO/CEA Organization, Stringent Pricing for Cost-Based Products: Govt Project Review
November 17, 2020
REGULATORY
- LDP, Ishin Strike Deal on OTC-Like Drugs, Patients to Pay “1/4” Special Charge
December 22, 2025
- Japan Set to Raise Medical Fees by 3% in FY2026, Cut Drug Prices by 0.8%
December 22, 2025
- LDP, Ishin Finalize FY2026 Tax Reform Outline, Strategic Tech R&D Credit Codified
December 22, 2025
- OTC-Like Drugs Left in Limbo as Panel Debates Cost-Sharing without Clear Policy Signal
December 19, 2025
- LDP, Ishin Fail to Seal Deal on OTC-Like Drugs as Talks Stall over Fiscal-Savings Figure
December 18, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…